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In an earlier Editor’s Page I indicated that nearly two-thirds
of submissions to JACC originated from outside of the U.S.
These manuscripts now receive an acceptance rate similar to
papers from within the country. There are a number of
possible explanations for the predominant number of inter-
national submissions, including an increasing quantity and
quality of research overseas, advantageous circumstances for
patient recruitment, and perhaps the desire to publish in
U.S. journals having a world-wide readership. However, one
possible explanation is diminished productivity of clinical
research within the U.S.
The National Institutes of Health (NIH) defines “clinical
research” to include: patient oriented research including
mechanisms of human disease, clinical trials, and new
technology development; epidemiologic and behavioral
studies; and outcomes and health services research. That
significant difficulties plague clinical research in the U.S. has
been recognized since 1979 when then NIH Director,
James Wyngaarden, described clinical investigators as “an
endangered species” (1). However, the recent stunning
advances in basic science have, by contrast, brought the
problems in clinical research into sharp focus.
Anxiety regarding clinical research has reached a suffi-
cient level that several groups have addressed the problem.
Representatives of government, private funders of research,
and health care payers met for over a year to issue a Clinical
Research Summit Report, frequently referred to as the
“Graylyn Report” (2). In the March 12 issue of JAMA, the
Clinical Research Roundtable (CRR), a diverse group of
stakeholders assembled by the Institute of Medicine, re-
ported the results of over two years’ deliberations on the
topic (3). Concern has been expressed that the lack of
dedicated clinical investigators and supporting infrastructure
is slowing the translation of insights derived in the research
laboratory into benefits accruing to patients at the bedside.
Specifically, the Graylyn Report emphasizes that “many
elements of the complex ecosystem that support clinical
research are shifting or eroding.”
The CRR identified two major obstructions to converting
new scientific knowledge into enhanced human health:
translation of basic science discoveries into new preventive,
diagnostic, and therapeutic modalities; and implementation
of these new modalities into standard patient care. Clearly,
neither barrier can be overcome without a thriving clinical
research enterprise. The CRR recognized a number of
obstacles confronting clinical research in the U.S., including
rising costs and increased regulatory burdens. However, four
problems were of particular importance: lack of patients,
inadequate information systems, insufficient funding, and
the need for well-trained clinical investigators. Although all
are important, my own familiarity and concern is greatest
for the plight of clinical investigators.
Recent years have witnessed our increasing appreciation
for the courage and altruism of individuals volunteering for
clinical research. However, as detailed in the CRR report,
only 5% of the subjects screened for clinical trials actually
complete the protocol, and by 2005 nearly 20 million
individuals will have to be screened to fulfill the need of
industry trials alone. Enrollment has surely been hurt by the
adverse events experienced by some subjects, and by the
potential conflict of interest of some investigators widely
disseminated in the media. Research participants must have
more understanding and ownership of the process. Getting
patients to appreciate the importance of evidence-based
medicine and how evidence is acquired could go a long way
in this regard. However, it is also incumbent upon all
cardiologists to encourage, facilitate, and even direct their
patients to participate in clinical studies. The U.S. lacks the
medical regionalization of most of the rest of the world, and
the health care system fosters a strong sense of preserving
our own patient population. For clinical investigation to
thrive in the U.S., the active participation of all cardiovas-
cular specialists will be required, whether in academia,
private practice, or in other settings.
Just as medical records often continue to be generated
manually and stored on paper, informatics have not made
great inroads into the process of clinical investigation.
Obviously, application of modern information technology
could markedly reduce the time and effort in clinical
research. Sophisticated information systems would, of
course, require substantial increase in funding, another of
the major challenges identified for clinical research. How-
ever, nowhere is the need for increased support more
important than with respect to clinical investigators.
Clinical investigators are the base upon which the clinical
research enterprise is built. However, the number of physi-
cians pursuing a career in research has declined since the
mid-1980s, as has the number of medical students planning
a career in clinical research (4). A 47% decrease in physi-
cians applying for research fellowships has occurred between
1995 and 2001, and currently only 8% of principal investi-
gators conducting industry-sponsored clinical trials are un-
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der age 40 (3). The pool of clinical investigators may not
only be unable to translate the new basic science discoveries
into better care, but may not even be sufficient to continue
the present level of efforts. This will be particularly true in
cardiovascular medicine, where a significant shortage of
specialists is projected to occur as early as 2010.
A number of impediments confront physicians contem-
plating a career in clinical research. Many physicians face a
heavy debt upon graduation, and the prospect of spending
additional years of training required for a research career at
a relatively low pay scale is unappealing and often prohibi-
tive. Although “on the job training” was the rule for
producing clinical investigators in previous years, the need
for specialized training is now well recognized, and there is
a pressing need for more such training programs. Debate
continues as to whether clinical investigators are born or can
be produced, but all recognize that inquisitiveness, innova-
tion, and imagination are traits that are difficult to teach.
Accordingly, leakage from the system of productive clinical
researchers is particularly painful.
The lack of academic prestige is often cited as a strong
disincentive to embark on or continue in a clinical research
career. Clinical investigation is often regarded as a tier
below basic science, although all admit that the variables
involved in studying humans are often much more difficult
than those encountered in the experimental laboratory. The
criteria for promotion at most medical schools emphasize
independence and originality, although much clinical re-
search involves collaborative efforts to address existing
unresolved issues. Compared to basic science, the criteria for
excellence in clinical research are more difficult to define.
Even when promotion is accorded, it is often in a different
appointment series than basic scientists. When financial
disincentives—including a lesser pay than colleagues in
practice—are added to the above impediments, it is not
surprising that many of the “best and brightest” physicians
choose clinical practice. We are fortunate that the thrill of
discovery, pride of mentorship, and satisfaction of defining
best care for other physicians are sufficient to keep so many
excellent individuals in clinical research.
A special word seems in order about the role of mentors.
As one whose career shifted from private practice to clinical
research due to role models, I can attest to the importance
of mentors in attracting and creating new clinical investi-
gators. Today there is a progressively diminishing number
of mentors, and they often function under very difficult
circumstances. Clinical investigators are very often expected
to generate the bulk of their salary from patient care
collections. Although in the past one could generate an
academic salary with part-time practice, reduced reimburse-
ment and underinsured patients now require virtually full-
time commitment. Since grant funding for clinical research
is scarce, patient-based investigation must often be piggy-
backed onto clinical services. Reduced house staff and fellow
numbers now require more direct faculty coverage of patient
care than was previously required. Current requirements for
documentation are now likewise much more time consum-
ing. Thus, the clinical researcher is often left with little time
and financial support to devote to investigation—much less
for mentoring. Confronted with teachers who appear
stressed, it is not surprising that trainees will choose
alternate career paths. In my opinion, we will not be able to
sustain a productive clinical research enterprise until the
challenges confronting mentors are addressed.
The problems facing clinical investigation are not new,
nor is their recognition. However, with the passage of time
they have become more severe, so that the term “impending
crisis” is likely not too strong a description. The voices
recognizing the problem and recommending solutions have
grown progressively louder. I believe that most responsible
agencies will heed the chorus issuing a call to action. It is
clear that measures should be instituted to ensure greater
patient participation, that regulatory burdens will need to be
reduced, that state-of-the-art information technology
should be implemented, and that increased funding must be
directed to the effort. Most importantly, these measures as
well as others must serve to attract and nurture clinical
investigators. Absent such an effort, society will not realize
the health benefits available from the basic science research
in which it has successfully invested.
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